FENUGREEK SEED AND ITS ACTIVE AGENT DIOSGENIN TREATMENT EFFECTS ON DIFFERENT METABOLIC PARAMETERS IN RATS

ANDREA BADALE¹, ANNAMARIA PALLAG², MARIANNA KOZMA¹, CSABA HEGEDUS³, DIANA KOVACS¹, HAJNALKA GULYAS¹, MIHAELA ZDRINCA⁴, IOAN MAGYAR⁴, FELICIA MARC⁴, SEBASTIAN NEMETH²*, RITA KISS¹

¹Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt., H-4032 Debrecen, Hungary
²Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 29 Nicolae Jiga Street, R-410028 Oradea, Romania
³Cera-Med Ltd, 1 Kátvölgyi u., H-4225 Debrecen, Hungary
⁴Preclinical Disciplines Department, Faculty of Medicine and Pharmacy, University of Oradea, 10 1 Decembrie Square, R-410073 Oradea, Romania
⁵Medical Disciplines Department, Faculty of Medicine and Pharmacy, University of Oradea, 10 1 Decembrie Square, R-410073 Oradea, Romania

*corresponding author: sebinemeth@yahoo.com
⁴Authors with equal contribution

Abstract

In the present study we investigated the effects of chronic oral treatment with fenugreek seeds (Trigonella foenum-graecum, TFG) and diosgenin (DG), one of its saponins, on diet induced obese (DIO) rats. Under the six weeks long treatment period metabolic parameters such as body weight, food and water intake were daily measured. At the end of the 6 weeks we performed insulin tolerance test (ITT). After 6 weeks of high fat diet the animals developed obesity. TFG treatment worsened the effects of diet induced obesity on body weight, abdominal adiposity and energy intake, but it had no effect on insulin sensitivity. Diosgenin alone did not show significant effects on the examined parameters. We conclude that diosgenin alone did not cause any particular body weight or fat gain, but is likely to interact in a complex manner with the other ingredients of the fenugreek seeds.

Keywords: fenugreek, diosgenin, obesity, insulin resistance

Introduction

Obesity has reached epidemic proportions on a global level in the past few decades. Obesity is associated with an increased risk of developing insulin resistance and type 2 diabetes (T2DM), hypertension, atherosclerosis and certain tumours [6, 16, 27]. The lifestyle of western culture, which consists of an unhealthy diet and insufficient physical exercise, highly contributes to the development of obesity and related diseases. Despite the amount of scientific attention towards obesity, proper pharmacological therapy is still not available. However, there is a growing interest towards the possible therapeutic applications of natural bioactive compounds. Since ancient times, plants represent an excellent source of biologically active substances, and a large proportion of currently-available drugs are either derived directly or indirectly from plant sources [8, 22-24]. Literature suggests that there are more than 800 plants that may possess hypoglycaemic activity [10], this means that...
there might be a potential alternative in the treatment of T2DM. Although numerous medicinal plants are being used in supportive treatment of T2DM, a significant amount of research suggests that fenugreek seeds are among the best in terms of safety and efficacy [10, 14, 21, 24, 28, 34], containing numerous biologically active compounds, providing high medicinal and nutritional profile: fibre, phospholipids, glycolipids, oleic acid, linoleic acid, steroid sapogenins, 4-OH isoleucine, galactomannan and many other functional elements such as vitamins A, B1, B2, C, choline, nicotinic acid, niacin and minerals [1, 2, 10, 19]. The *Trigonella foenum-graecum* is also listed in the Pharmacopoeia. The Fenugreek seeds have also been shown to exert significant antiatherogenic, antidiabetic, antianorexic, antihyperlipidaemic, antioxidant, antiinflammatory and gastro-protective effects is several human and animal models [1, 24, 28, 32, 34-36]. Moreover, treatments with fenugreek seeds have multiple benefits in patients with diabetes mellitus [3]. Research in the past two decades has shown that fenugreek seeds have positive effect on blood glucose level and glucose tolerance in patients with diabetes mellitus [21]. Fenugreek has been shown to exert a significant impact on the metabolism of lipids and glucose, it is also insulin-sensitizing, has antioxidant effects, and it contributes to keeping the energy balance [3].

In the present study we investigated the effects of chronic oral treatment with fenugreek seeds and diosgenin, one of its saponins, on diet induced obese rats. Under the six week long treatment period we measured the body weight, food and water consumption on a daily basis. At the end point of the experimental protocol, on the sixth week, we measured the insulin sensitivity using insulin tolerance test.

### Materials and Methods

The study was in concordance with the Declaration of Ethics in Decommissioning 08/2007 DE MÅB and 16/2007 DE MÅB, and the study complied with the international (EU and US) Recommendation on the Treatment of Experimental Animals (published in 1996 at the National Academy Press, 2101 Constitution Ave. NW, Washington DC 20055, USA).

For the study we used a diet induced obesity rat model. The male Wistar rats (n = 60) were housed in an animal room with 22 - 24°C and 50 - 70% relative humidity. The lighting was set to 12 h light and 12 h dark period. After a week of acclimatization period, rats were equally and randomly assigned into six groups. Three animals per each group were individually placed into metabolic cages (3701M081, Tecniplast, Italy), the rest was kept in standard rat cages, 3 - 4 animal per cage. Rats in the control group were fed *ad libitum* with standard laboratory chow (S8106-S011 SM R/M-Z+H, ssniff Spezialdiäten GmbH, Germany) and tap water, and the other five groups were DIO animals. Obesity was induced with a special rodent chow rich in fat (high fat diet, HFD) (RM AFE 45%FAT 20%CP 35%CHO (P), Special Diets Services, UK) and 5% sucrose solution. DG in different concentrations (1, 10 and 50 mg/kg) or TFG seeds (0.6 g/kg) were mixed into the chow of the treated DIO rats (Table I). The experiment lasted for 6 weeks.

### Table I

<table>
<thead>
<tr>
<th>Groups</th>
<th>Diet</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control group</td>
</tr>
<tr>
<td></td>
<td>DG/TFG (mg)</td>
</tr>
<tr>
<td></td>
<td>HFD control group</td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>HFD 1 mg/kg DG</td>
<td>15.7</td>
</tr>
<tr>
<td>HFD 10 mg/kg DG</td>
<td>156.7</td>
</tr>
<tr>
<td>HFD 50 mg/kg DG</td>
<td>783.5</td>
</tr>
<tr>
<td>HFD 0.6 g/kg TFG seed</td>
<td>18201.9</td>
</tr>
</tbody>
</table>

### Metabolic measurements

For the animals kept in metabolic cages body weight, food- and water consumption, urine and stool production were measured every morning, except at weekends when a 3-days average was calculated on the next Monday morning. The body weights of the animals being kept in normal cages were measured twice a week, the food- and water consumption were determined on a daily basis. The amount of DG or TFG being mixed in the chow was calculated from the body weight and daily food consumption data every week.

The daily calorie intake was calculated according to the following formula: standard chow: 3.2 kcal/g, HFD: 4.56 kcal/g, 5% sucrose solution: 0.2 kcal/mL. At the end of the treatment period the abdominal white adipose tissue (retroperitoneal, gonadal) was removed and measured.

### Determination of insulin sensitivity

**Insulin tolerance test (ITT)** was carried out on week 6. Before the experiment, the animals were fasted for 3 hours, and then, the basal blood glucose levels were determined *via a tail clip*. Blood glucose concentration was determined by means of glucometer (Accu-Chek, Roche Diagnostics, Budaörs, Hungary). After basal
blood glucose measurements, 0.5 U/kg insulin was administered intraperitoneally, then blood glucose was measured at 30, 60, 90 and 120 min. Insulin tolerance was estimated from area under the glucose curve.

Statistics
All data were analysed with one-way analysis of variance (ANOVA) followed by a modified t-test for repeated measures according to Bonferroni’s method was used. Data were presented as mean ± SEM. *, ** and *** indicated significant difference compared to the control group (p < 0.05, p < 0.01 and p < 0.001, respectively). #, ## and ### indicated significant difference compared to the HFD control group (p < 0.05, p < 0.01 and p < 0.001, respectively).

Results and Discussion

Metabolic measurements
Figure 1 shows the effects of diosgenin and fenugreek seed treatment on body weight. The animals treated with 1 mg/kg diosgenin and 0.6 g/kg fenugreek seeds showed a significant increase from day 4 compared to healthy controls, and that significant difference was maintained throughout the experimental period.

The TFG is not a weight loss promoting agent, it is frequently used as a nutritional supplement in the treatment of diabetes mellitus, because of its blood glucose normalizing and insulin sensitizing effect, our research, however, demonstrated that the western diet combined with a small dosage of TFG increases the risk of weight gain or obesity. This novel observation can be considered as an important side effect of TFG, and it is our suggestion that patients who use TFG as food supplement, or physicians who prescribe it should take care of proper dosing to avoid the possible undesired effect of TFG on body weight. Diet rich in fat and sugar resulted in a significant difference in white adipose tissue (WAT) accumulation, however, there was no visible dose-response correlation between the different doses of diosgenin regarding adipose tissue weight, not even with the HFD 10 mg/kg DG group which showed the largest weight gain compared to healthy controls. Fenugreek on the other hand caused a significant increase compared to the control but not to the HFD control group, we observed that in high dosage, diosgenin and TFG manifest a tendency to decrease the amount of WAT (Figure 2).

On the contrary, low dosages of diosgenin and TFG seed are not able to counterbalance the effects of HFD. TFG seeds, besides causing obesity, also increase the abdominal WAT, which is in correlation with the appearance of diabetes mellitus.

Figure 1.
Effect of chronic diosgenin and fenugreek seed treatment on body weight gain
The *, ** and *** indicates significant difference compared to the control group (p < 0.05, p < 0.01 and p < 0.001, respectively)

Figure 2.
Effect of chronic diosgenin and fenugreek seed treatment on the weight of abdominal white adipose tissue
The * and ** indicates significant difference compared to the control group (p < 0.05 and p < 0.01, respectively)
Figure 3 and Figure 4 show the food and water consumption during the treatment period. We found that all HFD groups consumed significantly less food compared to the control group. At the same time water consumption increased significantly in the 10 mg/kg and 50 mg/kg diosgenin and fenugreek groups.

The daily calorie intake was determined as written above. High-fat diet contains more calories than normal chow, however, sucrose solution adds additional calories to the daily energy intake in the HFD groups. We found that the HFD control and the diosgenin treated group took the same amount of calories per day compared to the control group. However, the energy intake of the fenugreek treated rats was significantly increased compared to the HFD control and diosgenin treated groups, as shown in Figure 5. The rats ate less during the experimental period (Figure 3), but their calorie intake has increased due to the high fat diet containing a great amount of energy as shown in Figure 5. This can explain why the TFG increases not only the abdominal WAT, but the body weight as well.

In addition, the animal cages were not supplied with running wheel or other means that could have allowed the rats to burn the excessive calories ingested, therefore they could not compensate for the increased energy intake, and consequently, the balance between energy consumption and energy expenditure is turned towards weight gain.

Our results show that while the diet induced obese rats reduced food intake to compensate for the energy rich diet, they gained body weight at a larger rate, and in HFD controls the weight of abdominal white
adipose tissue was significantly elevated. Diosgenin treatment alone was unable to balance the negative effects of high fat diet on body weight, adiposity and energy metabolism. In turn, our data pointed out that chronic treatment with fenugreek seed worsened the aforementioned parameters, which suggests that it is not diosgenin, but other bioactive compounds present in TFG that are responsible for the metabolic alterations. Recent research result highlighted the role of 4-OH isoleucine or galactomannan in the glucose tolerance improving and insulin sensitizing effect of fenugreek seeds [5, 12, 20, 30]. The effect of fenugreek in body weight gain might be related to the well-established fact that TFG is able to act on hormones in the central nervous system involved in the regulation food intake such as melanin concentrating hormone (MCH). Fenugreek is able to act as an MCH agonist [7, 9, 11, 13, 17, 18, 25, 29, 33].

Insulin sensitivity

During the insulin tolerance test there was no difference regarding the area under the curve between groups (Figure 6, Figure 7).

Our data showed that despite TFG enhanced weight gain and increased abdominal adiposity, parameters well connected to the development of insulin resistance, 6 weeks treatment with fenugreek seeds didn’t alter insulin sensitivity. It is well established that fenugreek has an insulin sensitizing effect [4, 5, 15, 25, 30, 31] and delays the development of glucose intolerance in sensitive patients, but our results with diosgenin could not corroborate this, which suggests that sapogenins do not play a significant role in the insulin sensitizing effect of TFG, and the applied dose of TFG is not enough to increase insulin sensitivity in the DIO model.

Conclusions

Chronic treatment with fenugreek increased the body weight gain caused by fat and sugar rich diet. Abdominal adiposity and consumed calories in the TFG group was also increased compared to control and DIO control animals. But despite its negative effects on body weight, abdominal fat and energy intake, fenugreek treatment failed to negatively modify insulin sensitivity of the peripheral tissues. In our experimental protocol we demonstrated that lower doses of diosgenin and an appropriate dose of TFG in combination with a diet containing a higher number of calories can increase the risk of obesity. Our finding should be taken in consideration concerning patients who take TFG as a nutritional supplement to normalize blood glucose levels, alone or in a combination with specific antidiabetic therapy. Although the literature supports the insulin sensitizing effect of the TFG, we failed to demonstrate this effect, probably because of the relatively small dose used in our research.

We conclude that diosgenin alone does not cause any particular body weight or fat gain, but is likely to interact in a complex manner with the other ingredients of the Fenugreek seed synergistically, but further research is needed to clearly highlight the mechanisms and the role of the active ingredients involved.
Further investigations will be carried out, with other doses of TFG, and also there will be performed other methods in the determination of insulin sensitivity, such as glucose tolerance test and hyperinsulinaemia euglycaemic glucose clamp.

Acknowledgement
This study was supported by the Hungarian-European Research Infrastructure Network (EFOP-3.6.2-16-2017-00009).

References


